Dr. Michelle Reinhardt has been a board-certified psychiatric pharmacist (BCPP) practicing in Montana since 2014. She earned her Doctor of Pharmacy (PharmD) degree from Roseman University in Southern Nevada, followed by postgraduate residency training in Clinical Pharmacy at Billings Clinic and in Psychopharmacology at The University of Texas at Austin.

Following residency, Dr. Reinhardt joined Billings Clinic, where she established the organization’s first inpatient psychopharmacology service line. In this role, she collaborated closely with psychiatric providers to ensure safe, effective, and evidence-based treatment for individuals with mental health and substance use disorders. She was also a founding member of Project ECHO Billings Clinic, supporting interdisciplinary education and consultation for healthcare providers across Montana.

In the latter part of her time at Billings Clinic, Dr. Reinhardt joined the University of Washington Psychiatry Residency – Montana Track faculty, where she provided psychopharmacology education, training, and supervision to PGY-3 and PGY-4 psychiatry residents.

In December 2022, she joined 406 Recovery as Chief Scientific Officer, bringing her expertise in psychopharmacology to support the organization’s mission of delivering compassionate, evidence-based care across Montana.

Her professional interests include evidence-based psychopharmacology, pharmacokinetics, pharmacodynamics, pharmacogenetics, and interdisciplinary education of residents and students. Dr. Reinhardt is board certified in psychopharmacology through the American Association of Psychiatric Pharmacists (AAPP).